Low T Lawsuits: Manufacturers Marketing Tactics

September 28, 2015 – – Banville Law reports on low t lawsuits and the advertising tactics of low testosterone drug manufacturers. Low Testosterone drug ads make many promises, indicating that the drugs work much like the fictional and deeply sought-after fountain of youth. Among the advertising concepts noted were regaining your former glory and leaving your wives speechless. Other ads described those in need of low testosterone drugs as “feeling like a shadow of (their) former self” and having lost their “appetite for romance.”

These alleged conditions and outcomes are ones that low testosterone drug manufacturers highlight in their advertisements. The solution they propose is low testosterone drugs. Due in part to the previously described advertising, these drugs, originally intended to be prescribed to people suffering from conditions due to significantly low testosterone levels such as hypogonadism, have now turned into a $2 billion industry annually, and are used to “fight” many of the general, normal symptoms of aging.

Just as the popularity of low t drug use has increased, so has the controversy around it. The Food and Drug Administration took action when studies seemed to link the drug to strokes and heart attacks. The FDA issued a warning of potential increased risks for heart attack and stroke for anyone using low testosterone drugs. Additionally, they have required drug manufacturers to publish more explicit warnings on their low t product labels, warning consumers of their possible serious side effects.

In addition to these warnings, there are now over 2,500 lawsuits from consumers who have suffered health problems after using the drugs. Many of the lawsuits have been consolidated into multidistrict litigation in a Chicago courtroom and will be presided over by the Honorable Judge Matthew F. Kennelly. The plaintiff allegations have many commonalities, and generally indicate aggressive, misleading marketing and advertising tactics as well as health risks connected to the various low t drugs such as blood clots, stroke, heart attacks, and even death.

Defendants include several large pharmaceutical manufacturing companies, the first of which to be reviewed is AbbVie Inc., maker of AndroGel, one of the most popular low t drugs on the market. In the first half of 2015, AndroGel sales generated $320 million in revenue. This number, however, was down by almost a third from last year’s numbers, possibly because of the health concerns that have recently come to light.

Those who have suffered from serious health complications after using a low testosterone drug may be entitled to legal action. Laurence Banville, Esq. of Banville law is currently reviewing cases for those involved, and also sponsors the website LowTestosteroneCase.com, where additional information on this topic and surrounding low t lawsuits can be found.

To speak with Laurence Banville, Esq., call 917-809-6595.

###

Contact Banville Law:

Laurence Banville, Esq.
888-478-9711
info@banvillelaw.com
165 West End Avenue, #1H
New York, NY 10023
United States (US)

ReleaseID: 60004420